FDA
-
-
-
-
-
-
-
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
-
-
-
-
-
-
-
Valion Bio regains Nasdaq minimum bid price compliance
-
-
-
-
-
-
-
AFRRI begins government-funded Entolimod radiation injury study
-
-
-
-
-
-
-
AFRRI and NIAID complete protocol to test Valion Bio's Entolimod
-
-
-
-
-
-
-
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
-
-
-
-
-
-
-
Tivic Health rebrands to Valion Bio, changes ticker to VBIO
-
-
-
-
-
-
-
Vitality Biopharma Inc. (VBIO) granted FDA Orphan Drug Designations for treatment of pediatric ulcerative colitis between the ages of 0-18 years
-
335,483 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


